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ORIGINAL ARTICLE
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Background: Microseminoprotein-beta (MSP), a protein secreted by the prostate epithelium, may have a protective role in the
development of prostate cancer. The only previous prospective study found a 2% reduced prostate cancer risk per unit increase
in MSP. This work investigates the association of MSP with prostate cancer risk using observational and Mendelian
randomization (MR) methods.
Patients and methods: A nested case–control study was conducted with the European Prospective Investigation into Cancer and
Nutrition (EPIC) with 1871 cases and 1871 matched controls. Conditional logistic regression analysis was used to investigate the
association of pre-diagnostic circulating MSP with risk of incident prostate cancer overall and by tumour subtype. EPIC-derived
estimates were combined with published data to calculate an MR estimate using two-sample inverse-variance method.
Results: Plasma MSP concentrations were inversely associated with prostate cancer risk after adjusting for total prostate-
specific antigen concentration [odds ratio (OR) highest versus lowest fourth of MSP¼ 0.65, 95% confidence interval (CI)
0.51–0.84, Ptrend¼ 0.001]. No heterogeneity in this association was observed by tumour stage or histological grade. Plasma
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MSP concentrations were 66% lower in rs10993994 TT compared with CC homozygotes (per allele difference in MSP: 6.09 ng/ml, 95%
CI 5.56–6.61, r2¼0.42). MR analyses supported a potentially causal protective association of MSP with prostate cancer risk (OR per 1 ng/
ml increase in MSP for MR: 0.96, 95% CI 0.95–0.97 versus EPIC observational: 0.98, 95% CI 0.97–0.99). Limitations include lack of
complete tumour subtype information and more complete information on the biological function of MSP.
Conclusions: In this large prospective European study and using MR analyses, men with high circulating MSP concentration
have a lower risk of prostate cancer. MSP may play a causally protective role in prostate cancer.
Key words: prostate cancer, microseminoprotein-beta, prostate-speciﬁc antigen, prospective study, EPIC cohort, Mendelian
randomization
Introduction
Microseminoprotein-beta (MSP) is a protein secreted by the
prostate epithelium into the seminal fluid [1]. In the only previ-
ous prospective study, the Multiethnic Cohort (MEC) [2], a 1 ng/
ml increase in circulating MSP concentration was associated with
a 2% decrease in prostate cancer risk. MSP concentrations, in
both blood and semen samples from healthy males, are 60%
higher among CC homozygotes versus TT homozygotes for
rs10993994 (r2 ¼ 0.38 and 0.23, respectively), located 57 base-
pairs upstream in the 50 promoter region of the MSMB gene [3],
which encodes the protein MSP. Furthermore, a genome-wide
association study (GWAS) has found carriers of the T allele to
have an elevated prostate cancer risk (57% higher for TT versus
CC) [2, 4].
This prospective study investigated whether circulating MSP
concentrations were associated with prostate cancer risk in the
European Prospective Investigation into Cancer and Nutrition
(EPIC). We then investigated the association of rs10993994
with circulating concentrations of MSP in EPIC and used this
genetic variant as an instrument for MSP to assess its potential
causal role through Mendelian randomization (MR) analyses
by combining EPIC-derived estimates with published data
from the Prostate Cancer Association Group to Investigate
Cancer Associated Alterations in the Genome (PRACTICAL)
consortium [5].
Methods
Study population
Totally, 137 000 men participating in EPIC provided blood samples at re-
cruitment between 1992 and 2000 [6]. Lifestyle questionnaires, anthropo-
metric data, and food questionnaires were collected at recruitment. All
participants provided written informed consent. Approval for the study was
obtained from the ethical review boards of the participating institutions and
the International Agency for Research on Cancer (IARC). The current study
uses data from Germany, Greece, Italy, the Netherlands, Spain and the UK.
Follow-up
Cancer incidence was identified through record linkage to regional or na-
tional registries in most countries (see supplementary methods, available
at Annals of Oncology online). Follow-up procedures continued to pros-
tate cancer diagnosis or last follow-up completed (31 December 2007 to
14 June 2010).
Cases were men who were diagnosed with incident prostate cancer
(International Classification of Diseases 10th revision code C61 [7]) after
blood collection and before the end of follow-up. An incidence density
sampling protocol was used to select control participants at random
from the cohort of men who were alive and free of cancer (excluding
non-melanoma skin cancer) at the time of diagnosis of the index case and
who matched on study centre, length of follow-up, age at blood collec-
tion, time of blood collection and duration of fasting at blood collection.
These analyses included 1871 cases with 1871 matched controls.
Information on tumour stage and grade at diagnosis was available for
1263 (67.5%) and 1554 (85.1%) of cases, respectively (see supplementary
methods, available at Annals of Oncology online).
Assessment of analytes
Immunoassay measurements for prostate-specific antigen (PSA) [8] and
MSP [9, 10] were conducted on the AutoDelfia
VR
1235 automatic im-
munoassay system in Dr Lilja’s laboratory at the Wallenberg Research
Laboratories, Department of Translational Medicine, Lund University,
Ska˚ne University Hospital, Malmo¨, Sweden (see supplementary methods,
available at Annals of Oncology online).
Statistical analysis
Analyte concentrations below limits of detection were set to half the low-
est concentration (PSA, N¼ 7), and concentrations above the upper lim-
its were set to the highest value for that analyte (MSP, N¼ 82; PSA,
N¼ 65). Pearson’s v2 tests and paired t-tests were conducted between
matched case–control sets for anthropometric and lifestyle characteris-
tics. Analysis of variance was used to assess differences in analyte concen-
trations in controls by strata of selected characteristics, country and study
phase (matched case–control sets were identified after each of three
rounds of follow-up and end point data centralisation in EPIC conducted
in approximately 2004, 2008 and 2010, and samples from each phase
were assayed together). Log transformations were applied to analyte con-
centrations and results are presented as geometric means adjusted for age
at blood collection, body mass index (BMI), recruitment centre and la-
boratory batch.
Conditional logistic regression models were used to examine the asso-
ciation of MSP with prostate cancer, conditioned on the matching factors
and adjusted for BMI, age at blood collection and further adjusted for
fourth of PSA concentration (additional adjustment was shown to not
materially alter the results, see supplementary Table S1, available at
Annals of Oncology online). These analyses were repeated in subgroups
according to study phase, time between blood collection and diagnosis,
age at blood collection, age at diagnosis, prostate tumour stage and histo-
logical grade. Additional unconditional analyses stratified by median
PSA concentration and smoking status were adjusted for age, BMI, fourth
of PSA concentration and matching factors. Linear trend was tested using
a pseudo-continuous variable equal to medians of the fourths of MSP
concentration. For subgroup analyses, likelihood ratio tests were used to
test for heterogeneity.rs10993994 genotype data were available for a sub-
set of 1068 EPIC cases and 1186 EPIC controls from the iCOGS [11],
OncoArray [12] and Breast and Prostate Cancer Cohort Consortium
(BPC3) [13] genotyping projects. Logistic regression models were used
to investigate the association of rs10993994 with prostate cancer.
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We investigated the potential causal role of MSP in prostate cancer risk
using MR analyses. A summary estimate of the association of rs10993994
with prostate cancer was taken from the iCOGS genotyping project in the
international consortium PRACTICAL with 25 000 cases from 32 studies [5,
11], and from EPIC prostate cancer cases and controls genotyped in the
OncoArray [12] and BPC3 studies [13]. Summary estimates for the associ-
ation of rs10993994 with MSP were calculated using these EPIC data [12,
13]. We used the MR-Base platform to do a phenome-wide association scan
for rs10993994 with 850 traits to check for pleiotropy [14], and also checked
the NHGR-EBI catalogue of published GWAS [15]. Two-sample MR esti-
mates were calculated separately using summary estimates for each of
PRACTICAL (iCOGS) [5] and EPIC-derived rs10993994-prostate cancer
risk estimates with the EPIC-derived rs10993994-MSP estimate, which were
then combined using the inverse-variance weighted method. To address
possible confounding by PSA, we conducted sensitivity analyses using the
summary association of rs10993994 with residuals from a linear regression
of log total PSA on MSP, also calculated within EPIC.
All statistical tests are two-sided and were conducted using STATA
software version 14 (StataCorp LP, College Station, TX).
Results
Data from 1871 cases and 1871 matched controls were included
in the analyses. The median age at blood collection was 58 years,
and, for cases, the median time between blood collection and
diagnosis was 8.3 years. No significant differences were observed
in selected baseline characteristics between cases and controls
(Table 1).
Mean MSP concentration (ng/ml) at blood collection did not
differ significantly between cases and controls (Table 1). Mean
PSA concentration (ng/ml) measured at blood collection was
about threefold higher in cases than controls [adjusted geometric
Table 1. Characteristics of control participants and prostate cancer patients
Characteristicse Controls
(n5 1871)
Cases
(n5 1871)
Pa
Age at blood collection (years)b 58.3 (6.9) 58.3 (6.9) 0.5
Weight (kg)b 80.2 (11.6) 80.2 (11.5) 0.5
Height (cm)b 172.9 (7.2) 172.5 (7.1) 0.9
BMI (kg/m2)b 26.9 (3.5) 27.1 (3.5) 0.2
Smoking status, n (%)
Never 578 (31.5) 621 (34.5)
Previous 826 (45.1) 792 (43.9)
Current 431 (23.4) 389 (21.6) 0.1
Alcohol, n (%)
<8 657 (34.8) 682 (36.4)
8–15 368 (19.9) 363 (19.4)
16–39 542 (28.9) 491 (26.2)
>40 304 (16.3) 335 (17.9) 0.3
Physical activity, n (%)
Inactive 277 (15.1) 268 (14.9)
Moderately inactive 533 (29.1) 525 (29.4)
Active 1025 (55.9) 996 (55.7) 0.9
Marital status, n (%)
Married/cohabitating 1377 (89.7) 1333 (88.6)
Not married/cohabitating 160 (10.4) 172 (11.4) 0.3
Educational attainment, n (%)
Primary/none 687 (38.3) 668 (38.3)
Secondary 633 (35.4) 596 (34.1)
Degree 471 (26.3) 482 (27.6) 0.6
Geometric mean analyte concentration at blood collection
MSP (ng/ml) (95% CI) 12.8 (12.5–13.2) 12.9 (12.6–13.2) 0.7
MSP adjusted for PSA (ng/ml)
(95% CI)
12.9 (12.6–13.3) 12.8 (12.5–13.1) 0.5
PSA (ng/ml) (95% CI) 0.8 (0.8–0.9) 2.4 (2.3–2.5) <0.0001
Time to diagnosis, n (%)
<2 years 81 (4.4)
2 to <4 years 111 (5.9)
4 to <6 years 244 (13.1)
6 to <8 years 375 (20.2)
8 to <10 years 1049 (56.4)
Year of diagnosis, median (range) 2004 (1994–2009)
Age at diagnosis (years) (SD) 66.9 (6.9)
Tumour stage
TNM-codec
Tumour
T1 176 (19.4)
T2 529 (58.4)
T3 183 (20.2)
T4 18 (1.9)
Nodes
N0 609 (92.3)
N1 46 (6.9)
N2 4 (0.1)
N3 1 (0.01)
Metastases
M0 522 (94.7)
M1 29 (5.3)
EPIC stage informationc
Localized 778 (82.4)
Metastatic 205 (21.7)
Tumour grade
Gleason graded
6 452 (55.7)
7 218 (28.6)
8 120 (15.7)
Continued
Table 1. Continued
Characteristicse Controls
(n51871)
Cases
(n51871)
Pa
EPIC grade informationd
Well differentiated 139 (16.6)
Moderately differentiated 503 (60.1)
Poorly differentiated 191 (22.8)
Undifferentiated 4 (0.1)
PSA (ng/ml) at diagnosis
<3 20 (3.6)
3 and <10 335 (59.8)
10 and <50 187 (33.4)
50 18 (3.2)
aP-values are from analysis of variance models where characteristics are
continuous and v2 test where characteristics are categorical.
bGeometric means are presented with standard deviation.
cTNM-code and EPIC stage are not mutually exclusive as some individuals
had information for both.
dGleason grade and EPIC grade are not mutually exclusive as some indi-
viduals had information for both.
eNumbers may not sum to total due to missing values.
BMI, body mass index; MSP, microseminoprotein-beta; CI, conﬁdence
interval; PSA, prostate-speciﬁc antigen; SD, standard deviation; EPIC,
European Prospective Investigation into Cancer and Nutrition.
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means¼ 2.4, 95% confidence interval (CI) 2.3–2.5 and 0.8, 0.8–
0.9 respectively, P< 0.0001].
MSP concentration in controls was higher in men older at
blood collection, not married, with normal/low BMI or low-alco-
hol intake, and who had higher educational attainment (P< 0.05
for all). Compared with never smokers, men who smoked more
than 15 cigarettes per day had 30% higher MSP concentrations
(Ptrend< 0.0001). PSA concentration was positively associated
with age at blood collection and educational attainment, and
negatively associated with greater BMI and diabetes (Table 2).
MSP and PSA concentrations were positively correlated in both
cases and controls (partial correlations r¼ 0.3 and 0.2, respective-
ly, P< 0.0001).
MSP concentration was not associated with prostate cancer
risk after adjustment for age at blood collection and BMI [odds
ratio (OR) for highest versus lowest fourth¼ 0.98, 95% CI 0.82–
1.19, Ptrend¼ 0.9)]. However, after adjustment for PSA, MSP
concentration was associated with prostate cancer risk
(OR¼ 0.65, 95% CI 0.51–0.84, Ptrend¼ 0.001) (Table 3). There
was some evidence of heterogeneity in the association by time to
diagnosis (with a stronger association in men diagnosed within
8.5 years of baseline, Pheterogeneity¼ 0.009), age at diagnosis
(Pheterogeneity¼ 0.03); (supplementary Table S2, available at
Annals of Oncology online) and recruitment country
(Pheterogeneity¼ 0.02; supplementary Table S3, available at
Annals of Oncology online). There was no significant
Table 2. Adjusted geometric mean MSP and PSA concentration (ng/ml) in controls by selected characteristics
Factor and subset MSP (ng/ml) PSA (ng/ml)
N Mean (95% CI)a P-difference/linear trendb N Mean (95% CI)a P-difference/linear trendb
Age at blood collection (years)
<50 195 11.7 (10.8–12.6) 195 0.6 (0.5–0.6)
50–55 339 12.3 (11.6–13.1) 339 0.7 (0.6–0.7)
55–59 503 12.2 (11.7–12.9) 503 0.8 (0.7–0.9)
60–64 549 12.7 (12.1–13.3) 549 0.9 (0.9–1.0)
65–69 169 15.4 (14.2–16.8) 169 1.3 (1.1–1.4)
>70 116 16.8 (15.2–18.6) <0.0001/<0.0001 116 1.6 (1.3–1.8) <0.0001/<0.0001
Time of blood collection (h)
00:00–09:59 305 13.0 (12.1–13.9) 306 0.9 (0.8–1.0)
10:00–12:59 267 13.6 (12.6–14.6) 267 0.8 (0.7–0.9)
13:00–23:59 1176 12.4 (12.0–12.9) 0.1 1176 0.8 (0.8–0.9) 0.03
Marital status
Married/cohabitating 1377 12.9 (12.5–13.2) 1377 0.8 (0.8–0.9)
Not married/cohabitating 160 14.3 (13.1–15.6) 0.01 160 0.9 (0.8–1.0) 0.9
Educational attainment
Primary/none 687 12.3 (11.8–12.8) 687 0.8 (0.7–0.8)
Secondary 633 13.2 (12.7–13.8) 633 0.9 (0.8–0.9)
Degree 471 12.8 (12.2–13.5) 0.02 471 0.9 (0.8–0.9) 0.02
Body mass index (kg/m2)
16–24 542 13.7 (13.1–14.3) 542 0.9 (0.8–0.9)
25–29 1003 12.8 (12.3–13.2) 1003 0.8 (0.8–0.9)
>30 317 11.7 (10.9–12.4) 0.0007/0.001 317 0.7 (0.7–0.8) 0.02/<0.001
Smoking status
Never 578 11.9 (11.4–12.4) 578 0.9 (0.8–0.9)
Previous 826 12.1 (11.7–12.6) 826 0.8 (0.8–0.9)
Current (<15 cigarettes) 181 15.8 (14.6–17.1) 181 0.9 (0.8–0.9)
Current (15 cigarettes) 154 17.0 (15.6–18.6) <0.0001/<0.0001 154 0.8 (0.7–0.9) 0.9
Usual alcohol consumption (g/day)
<8 657 13.6 (13.0–14.2) 657 0.9 (0.8–0.9)
8–15 368 13.0 (12.3–13.8) 368 0.9 (0.8–0.9)
16–39 542 12.3 (11.8–12.9) 542 0.8 (0.8–0.9)
>40 304 11.9 (11.2–12.7) 0.002/<0.0001 304 0.8 (0.7–0.9) 0.3
Diabetic
No 1760 12.9 (12.5–13.2) 1760 0.9 (0.8–0.9)
Yes 97 12.1 (10.8–13.5) 0.5 97 0.7 (0.6–0.8) 0.02
aAll means adjusted for age at blood collection, body mass index, recruitment centre and batch; adjustment not made for age at blood collection
excluded for strata of age at blood collection, nor body mass index for strata of body mass index.
bP-values are from analysis of variance and, where signiﬁcant difference was observed and dose-dependent relationship implied, from test for linear trend.
MSP, microseminoprotein-beta; PSA, prostate-speciﬁc antigen; CI, conﬁdence interval.
Original article Annals of Oncology
986 | Smith Byrne et al. Volume 30 | Issue 6 | 2019
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/30/6/983/5432642 by U
niversity of Bristol Library user on 23 Septem
ber 2019
heterogeneity of risk by smoking status (Pheterogeneity¼ 0.6;
supplementary Table S2, available at Annals of Oncology online).
The association of MSP with prostate cancer did not differ by
tumour stage or grade, or age at blood collection (all
Pheterogeneity 0.05; Table 3 and supplementary Table S2,
available at Annals of Oncology online). Results were not material-
ly altered and no significant heterogeneity was observed with
high grade defined as Gleason score7 (supplementary Table S2,
available at Annals of Oncology online). MSP was associated with
risk of death from prostate cancer (OR¼ 0.40, 95% CI 0.18–0.89,
with adjustment for age, BMI and PSA; Table 3).
PSA concentration was strongly and positively associated with
risk for prostate cancer, both with and without adjustment for
MSP concentration (OR¼ 45.2, 95% CI 29.7–68.7, with adjust-
ment for age, BMI and MSP; supplementary Table S4, available at
Annals of Oncology online).
In a subset of 1068 cases and 1186 controls with rs10993994
genotype data there was a 6.09 ng/ml (95% CI 5.56–6.61) per
allele difference in MSP concentration, with highest concentra-
tions observed for CC homozygotes. rs10993994 explained 42%
of the variability of MSP. In controls, there was a 0.22 ng/ml
(95% CI 0.09–0.35) per allele difference in PSA concentrations,
with highest concentrations observed for TT homozygotes (sup-
plementary Table S5, available at Annals of Oncology online). In
this EPIC dataset, rs10993994 genotype was significantly associ-
ated with prostate cancer (OR CC versus TT¼ 0.73, 95% CI
0.57–0.93, Ptrend¼ 0.006) (supplementary Table S6, available at
Annals of Oncology online).
After correction for multiple testing, no significant association of
rs10993994 genotype was observed with potential confounders be-
yond PSA concentrations in controls (supplementary Table S7,
available at Annals of Oncology online). PheWAS using published
data [14, 15], showed that besides prostate cancer risk, rs10993994 is
associated only with the prostate cancer biomarkers PSA and pros-
tate cancer antigen 3 (PCA3) at the genome-wide significance level.
An inverse-variance weighted MR showed a one unit increase in
Table 3. Multi-variable adjusted odds ratios (95% CI) for prostate cancer by fourth of plasma MSP concentration, subdivided by selected factors
Fourth of MSP concentration (ng/ml)
1 2 3 4 P for
trenda
P for
heterogeneity
of trendsb
Overall Cases/controls, n 508/468 402/464 458/468 501/469
Median MSP (ng/ml) (range) 7 (1–9) 12 (9–13) 16 (13–18) 29 (18–90)
Basic OR (95% CI)c 1 (reference) 0.82 (0.68–0.99) 0.91 (0.76–1.09) 0.98 (0.82–1.19) 0.9
Adjusted OR (95% CI)d 1 (reference) 0.84 (0.65–1.09) 0.75 (0.58–0.97) 0.65 (0.51–0.84) 0.001
Stagee
Localised (n¼886) Cases/controls, n 243/229 194/221 214/209 235/225
Adjusted OR (95% CI)d 1 (reference) 0.86 (0.57–1.28) 0.77 (0.52–1.15) 0.64 (0.44–0.92) 0.02
Advanced (n¼377) Cases/controls, n 110/95 87/81 91/109 89/92
Adjusted OR (95% CI)d 1 (reference) 0.79 (0.44–1.43) 0.45 (0.25–0.79) 0.45 (0.24–0.82) 0.002 0.2
Gradee (Gleason 8 cut-off)
Low-intermediate (n¼1357) Cases/controls, n 384/349 281/338 346/354 345/315
Adjusted OR (95% CI)d 1 (reference) 0.83 (0.59–1.15) 0.76 (0.56–1.02) 0.63 (0.46–0.86) 0.004
High (n¼197) Cases/controls, n 53/49 44/48 36/38 63/62
Adjusted OR (95% CI)d 1 (reference) 0.86 (0.42–1.76) 0.68 (0.32–1.46) 0.73 (0.39–1.42) 0.3 0.7
Death from prostate cancer
(n¼169)
Cases/controls, n 43/45 38/42 46/40 42/42
Basic OR (95% CI)c 1 (reference) 1.06 (0.59–1.94) 0.89 (0.47–1.67) 0.98 (0.54–1.77) 0.8
Adjusted OR (95% CI)d 1 (reference) 0.84 (0.38–1.86) 0.59 (0.27–1.30) 0.40 (0.18–0.89) 0.02
aTest for trend was obtained by replacing the categorical variable with a continuous variable equal to the median concentration within each fourth of
plasma MSP concentration.
bTest for heterogeneity in the trends.
cEstimates are from logistic regression conditioned on the matching variables: centre, age at blood collection, follow-up time, fasting status and time of
day at blood collection, with adjustment for age and body mass index (continuous).
dAdditional to model ‘b’, adjustment was made for body mass index (fourths), and total PSA (fourths).
eTumour stage information was available for 1263 (67.5%) cases: 886 cases were clinically localized (deﬁned as tumour–node–metastasis staging score of
T1–T2 and N0/Nx and M0/Mx, or stage coded in the recruitment centre as localized); 377 were clinically advanced (T3–T4 and/or N1–N3 and/or M1, or
stage coded in the recruitment centre as metastatic). Tumour grade information at diagnosis was available for 1554 cases (85.1%): 1357 were low-inter-
mediate grade (deﬁned as Gleason score<8, or grade coded as well, moderately or poorly differentiated) and 197 were high-grade (Gleason score8, or
grade coded as undifferentiated).
CI, conﬁdence interval; MSP, microseminoprotein-beta; OR, odds ratio.
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circulating MSP concentrations (ng/ml) is associated with a 4% re-
duction in prostate cancer risk (OR¼ 0.96, 95% CI 0.95–0.97)
(Table 4), and was not altered after adjustment for PSA (supplemen-
tary Table S8, available atAnnals of Oncology online).
Discussion
In this large prospective study, we found a lower prostate cancer risk in
men with higher circulating concentrations of MSP after adjustment
for circulating PSA concentrations. MSP is a protein in the immuno-
globulin-binding factor family primarily secreted by epithelial cells,
which may have a role in tumour suppression[16] and pathogen de-
fence [17]. These findings are in agreement with the only other pub-
lished prospective investigation [2], which found an inverse
association between circulating MSP concentration and prostate can-
cer; in the MEC study, MSP concentration was inversely associated
with prostate cancer risk before and after adjustment for PSA, though
the association was much stronger after adjustment, as is to be
expected due to the strong positive association of PSA concentration
with risk and the moderate positive association of PSA with MSP. In
accordance with previous findings [2], we found no evidence that the
association of MSP with risk differed by tumour stage or grade, al-
though small numbers of cases in subgroups may have limited power
to evaluate heterogeneity. We found some modest evidence for hetero-
geneity by country and age at diagnosis, but the results are difficult to
interpret due to small numbers in subgroups and multiple statistical
tests.
Short follow-up time (3.8 years) and thus reverse causality was
previously suggested in MEC as a possible explanation for the
observed association. The present study has more than double
the average follow-up (8.3 years), and while we found some ob-
servational evidence that the inverse association between MSP
and prostate cancer is stronger for men diagnosed closer to blood
collection, the apparent differences by time to diagnosis may be
at least in part due to differences in the case mix, with cases diag-
nosed closer to baseline being more likely to be younger at diag-
nosis. Furthermore, our MR findings suggest that reverse
causality is unlikely to explain the overall relationship, with gen-
etic variation in MSP affecting lifetime levels of MSP.
MSP is also secreted at lower levels by epithelial cells in the trache-
obronchial tree [18, 19]. Smoking has been associated with a 2.5-
fold increase in expression of MSP in the airway epithelium when
compared with non-smokers [20]. Therefore, some variation in
MSP concentrations may be due to smoking-induced secretory cell
hyperplasia in the respiratory tract. To our knowledge, we are the
only study to report higher levels of MSP among current smokers
compared with non-smokers. We found no strong evidence of het-
erogeneity in the MSP association by smoking status but more data
are needed to examine this and particularly to assess the association
in non-smokers in whom any potential masking effect of smoking
on circulating MSP is not present.
The strength of the current MR result stems from the use of
rs10993994 as an instrumental variable; rs10993994 lies in the
promotor region of the MSMB region, the locus that encodes
MSP, and rs10993994 is strongly associated with circulating
MSP concentrations and prostate cancer [2, 5]. In general, the
use of variants in the cis-acting protein-encoding locus is one of
the most robust scenarios of MR [21] and a recent review of
MSP function [22] suggest the rs10993994 genetic association is
specific to MSP. An association of rs10993994 has been observed
with concentrations of prostate cancer markers PSA and PCA3
in prostate cancer controls [15], and it remains possible that
PSA may confound these results. However, given that the associ-
ations of rs10993994 with PSA and PCA3 levels are observed
only in controls and that MR results were materially robust to
adjustment for PSA concentration, the association of
rs10993994 with PSA (and PCA3) may arise from collider bias.
Such collider bias [23], which induces the association of
rs10993994 with PSA and PCA3 when stratifying on prostate
cancer disease status, should not invalidate the results of the MR
analysis (which is not stratified on disease status). Additionally,
for the biological role of PSA to confound these findings, PSA
would have to be causal to prostate cancer development for
which there is little evidence.
Conclusion
Using observational data from a prospective nested case–control
study and MR, this study supports a possible protective role of
MSP in the development of prostate cancer. Experimental studies
are needed to elucidate the mechanisms through which MSP may
influence prostate cancer development. If shown to be true from
randomized clinical trials, therapies that raise MSP levels may
provide novel opportunities for the treatment and prevention of
prostate cancer.
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